OpenURL Connection Search

Select item for more details and to access through your institution.

Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers.
Published in:
Journal of Medical Virology, 2021, v. 93, n. 3, p. 1766, doi. 10.1002/jmv.26485
By:
- Capetti, Amedeo F.;
- Borgonovo, Fabio;
- Morena, Valentina;
- Lupo, Angelica;
- Cossu, Maria Vittoria;
- Passerini, Matteo;
- Dedivitiis, Gianfranco;
- Rizzardini, Giuliano
Publication type:
Article
Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
Published in:
Virology Journal, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12985-024-02333-x
By:
- Colaneri, Marta;
- Scaglione, Giovanni;
- Fassio, Federico;
- Galli, Lucia;
- Lai, Alessia;
- Bergna, Annalisa;
- Gabrieli, Arianna;
- Tarkowski, Maciej;
- Ventura, Carla Della;
- Colombo, Valeria;
- Cordier, Laura;
- Bernasconi, Davide;
- Corbellino, Mario;
- Dedivitiis, Gianfranco;
- Borghetti, Silvia;
- Visigalli, Debora;
- Sollima, Salvatore;
- Casalini, Giacomo;
- Rizzardini, Giuliano;
- Gori, Andrea
Publication type:
Article
Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.
Published in:
2021
By:
- Capetti, Amedeo F;
- Stangalini, Carlo A;
- Borgonovo, Fabio;
- Mileto, Davide;
- Oreni, Letizia;
- Dedivitiis, Gianfranco;
- Lupo, Angelica;
- Cossu, Maria V;
- Bilardo, Lara;
- Giacomelli, Andrea;
- Galli, Massimo;
- Rizzardini, Giuliano
Publication type:
Letter to the Editor

Found: 3

Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers.

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.

Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.